Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.
about
Treating refractory leukemias in childhood, role of clofarabineTreating adults with acute lymphocytic leukemia: new pharmacotherapy options.Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma.Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients.Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan.Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.Clofarabine in leukemia.A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.The role of clofarabine in acute myeloid leukemia.Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemiaNovel therapies for relapsed acute lymphoblastic leukemia.Clofarabine: past, present, and future.Clofarabine: a new treatment option for patients with acute myeloid leukemia.Clofarabine: emerging role in leukemias.Clofarabine for the treatment of adult acute myeloid leukemia.The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study.Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemiaEmerging pharmacotherapies for adult patients with acute lymphoblastic leukemia.Emerging treatments in acute myeloid leukaemia.A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias.Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells.Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantationClofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: a review.Cloretazine for the treatment of acute myeloid leukemia.French "real life" experience of clofarabine in children with refractory or relapsed acute lymphoblastic leukaemia.Clofarabine for the treatment of acute lymphoblastic leukemia.Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia.Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases.Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.Emerging therapy for the treatment of acute lymphoblastic leukemia.Clofarabine for myelodysplastic syndromes.Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.Clofarabine in pediatric acute leukemia: current findings and issues.Targeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?Late-phase investigational approaches for the treatment of relapsed/refractory acute myeloid leukemia.
P2860
Q24647279-8F33ACE8-B8B2-43D0-AB16-81847ABFE88AQ30243925-30E0B3E0-2B7E-4C8E-B112-2C23A943C026Q33383571-69012A35-319E-4927-A12A-3550BAE7D043Q33394597-58163632-B580-4FFB-B40E-C193BD434D94Q33431558-469D2AF6-1FB5-4E08-ACDF-7081852FDB7BQ33702412-FD16B740-BF2C-405F-BA18-129D3D556DD4Q33949752-65334D9C-DA45-4608-B27D-4F9DA4CBEA59Q34150263-6C4EC638-4B6A-441E-B176-1523560B6569Q34267853-32863F67-2809-483E-A1C4-D45C57CD0696Q34298181-E9E3B736-01F4-44A9-B06C-377FD5DEE99CQ34385571-D67A90EA-E432-41CA-944A-FD9C69F58400Q34619129-A40955CF-124B-448F-8E93-6EB91EA76B5CQ34686726-6A48072B-2E54-4013-B0EF-83FB9B117704Q34982576-2FEC601B-093A-42AF-8774-053C1AE06E5AQ35000135-48A5F5BD-2CE9-4CE0-A9B0-B78F11D17FBDQ35009273-277DDAAF-ADC8-4244-A37F-C8A38800EB8EQ35060679-94F93C7E-6E39-42C8-BB4E-8944AF42A769Q35136616-FE0B6B90-7FE5-45C6-8FFA-3C1F842DB7AFQ35572057-2E2C48C0-DF7D-47E3-AA76-A6A567E10B19Q35643010-B7D89E45-D706-46A3-BD34-99DA8EEB27A4Q35740894-7F450494-4546-4E45-B037-FEFCDA31D2A7Q35779278-A4B38C67-7330-42C4-927D-66760FD23095Q35990683-B751A080-D9DE-4D55-875A-F42DF4D1BED3Q36094977-A6EB70F1-925D-4C17-B650-C52183BF8BA8Q36176670-778520D5-9F46-4796-8309-07D84FFF4793Q36326258-1B3393EF-FD43-4679-95FA-80DAB547F2E1Q36407434-0C6C48A1-1229-44A5-B1D8-88CFBC6EEFB4Q36689775-D3CEB3B8-AAC7-4B70-AD5F-62284A103F1FQ36731404-C41BB3C7-E9EB-47E1-B3CB-C2597C06CA32Q36915178-57E0A17D-9B25-4988-A0DC-A2CDDB6FD38FQ37140698-408B835D-CAB7-42A1-8FED-206C4B813B3FQ37347515-AE6CA7B2-8D54-45C7-8A85-EF5EA70C070DQ37424784-33487635-D25E-4189-B2B5-A56C0997504BQ37533323-CF9A2F99-5B88-4121-8BFC-7A7F60FD2715Q37670194-DA4CB5BA-4D9D-4CBD-9919-6A09687765F5Q37876909-E54D76F3-DCC2-48A3-BC3B-17B740EB14AAQ37937816-107DCFD0-62AD-4B2B-992F-1E4A1F0DF87DQ37987061-03044191-01FB-42C5-974F-E8AD40EAAA44Q37994256-E2055A3E-E282-488E-A9A9-866654A46C67Q38042705-A5E32F4E-957C-4A4D-A97C-5214BEC5C87A
P2860
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Phase I clinical and pharmacol ...... solid and hematologic cancers.
@en
Phase I clinical and pharmacol ...... solid and hematologic cancers.
@nl
type
label
Phase I clinical and pharmacol ...... solid and hematologic cancers.
@en
Phase I clinical and pharmacol ...... solid and hematologic cancers.
@nl
prefLabel
Phase I clinical and pharmacol ...... solid and hematologic cancers.
@en
Phase I clinical and pharmacol ...... solid and hematologic cancers.
@nl
P2093
P50
P356
P1476
Phase I clinical and pharmacol ...... solid and hematologic cancers.
@en
P2093
Fadlo Khuri
Nuhad Ibrahim
Peter Kozuch
Peter McLaughlin
Varsha Gandhi
P304
P356
10.1200/JCO.2003.04.031
P407
P50
P577
2003-03-01T00:00:00Z